Нейроэндокринные механизмы регуляции пищевого поведения (обзор)

Литература:
1. Баранов A. A. Профилактическая педиатрия: руководство для врачей. М.: ПедиатрЪ, 2015; 744 с.
2. Van Galen КА, Тег Horst KW, Booij J, et al. The role of central dopamine and serotonin in human obesity: lessons learned from molecular neuroimaging studies. Metabolism 2018; (85): 325-39.
3. Naef L, Pitman KA, Borgland SL. Mesolimbic dopamine and its neuromodulators in obesity and binge eating. CNS Spectr 2015; 20 (6): 574-83.
4. Kumar M, Chail M. Sucrose and saccharin differentially modulate depression and anxiety-like behavior in diabetic mice: exposures and withdrawal effects. Psychopharmacology (Berl) 2019; 236 (11): 3095-110.
5. McCuen-Wurst C, Ruggieri M, Allison КС. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N YAcad Sci 2018; 1411 (1): 96-105.
6. Park HJ, Lee SE, Kim HB, et al. Association of obesity with serum leptin, adiponectin, and serotonin and gut microflora in beagle dogs. J Vet Intern Med 2015; 29 (1): 43-50.
7. Ojeda-Rodriguez A, Morell-Azanza L, Azcona-Sanjulian MC, et al. Reduced serotonin levels after a lifestyle intervention in obese children: association with glucose and anthropometric measurements. Disminucion de los niveles de serotoninatrasunaintervencion de estilo de vidaenninosobesos: asociacion con glucosa у medidasantropometricas. Nutr Hosp 2018; 35 (2): 279-85.
8. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci 2010; 13 (5): 635-41.
9. Beeler JA, Faust RP, Turkson S, et al. Low Dopamine D2 Receptor Increases Vulnerability to Obesity Via Reduced Physical Activity, Not Increased Appetitive Motivation. Biol Psychiatry 2016; 79 (11): 887-97.
10. Crane JD, Palanivel R, Mottillo EP, et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med 2015; 21 (2): 166-72.
11. Watanabe H, Nakano T, Saito R, et al. Serotonin Improves High Fat Diet Induced Obesity in Mice. PLoS One. URL: https://doi.org/10.1371/journal. pone. 0147143 (14 Jan 2016).
12. Ailanen L, Ruohonen ST, Vahatalo LH, et al. The metabolic syndrome in mice overexpressing neuropeptide Y in noradrenergic neurons. J Endocrinol 2017; 234 (1): 57-72.
13. Kim YJ, Bi S. Knockdown of neuropeptide Y in the dorsomedial hypothalamus reverses high-fat diet-induced obesity and impaired glucose tolerance in rats. Am J Physiol Regul Integr Comp Physiol 2016; 310 (2): 134-42.
14. Листопадова А. П., Петренко Ю. В. Нейропептид Y: физиологическая роль и клиническое значение. Медицина: теория и практика 2018; (3): 157-62.
15. Додонова С. А., Белых A. E., Бобынцев И. И. Регуляторные пептиды семейства меланокортинов: биосинтез, рецепция, биологические эффекты. Курский научно-практический вестник «Человек и его здоровье» 2018; (1): 99-108.
16. Осипова А. А. Роль леп-тина в регуляции энергетического обмена и функционировании организмов живой природы. Окружающая среда и энерговедение 2019; (2): 55-82.
17. Vehapoglu A, Turkmen S, Terzioglu S. Alpha-Melanocyte-Stimulating Hormone and Agouti-Related Protein: Do They Play a Role in Appetite Regulation in Childhood Obesity? J Clin Res Pediatr Endocrinol 2016; 8 (1): 40-7.
18. Roseberry AG, Stuhrman K, Dunigan Al. Regulation of the mesocorticolimbic and mesostriatal dopamine systems by a-melanocyte stimulating hormone and agouti-related protein. Neurosci Biobehav Rev 2015; (56): 15-25.
19. Ikeda H, Ardianto C, Yonemochi N, et al. Inhibition of opioid systems in the hypothalamus as well as the mesolimbic area suppresses feeding behavior of mice. Neuroscience 2015; (311): 9-21.
20. Valbrun LP, Zvonarev V The Opioid System and Food Intake: Use of Opiate Antagonists in Treatment of Binge Eating Disorder and Abnormal Eating Behavior. J Clin Med Res. 2020; 12 (2): 41-63.
21. Гмошинский И. В., Апрятин С. А., Шипе-лин В. А. и др. Нейромедиаторы и нейропептиды — биомаркеры метаболических нарушений при ожирении. Проблемы эндокринологии 2018; 64 (4): 258-69.
22. Gruden G, Barutta F, Kunos G, et al. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol 2016; 173 (7): 1116-27.
23. ZinkAN, Bunney PE, HolmAA, etal. Neuromodulation of orexin neurons reduces diet-induced adiposity. Int J Obes (Lond) 2018; 42 (4): 737-45.
24. Gilon P. Cocaine- and amphetamine-regulated transcript: a novel regulator of energy homeostasis expressed in a subpopulation of pancreatic islet cells. Diabetologia 2016; 59 (9): 1855-9.
25. Munoz-Rodriguez JR, Agarrado A, Martin-Fernandez J, et al. Cocaine and amphetamine regulated transcript and brain-derived neurotrophic factor in morbid obesity. One-year follow-up after gastric bypass. Surg Obes Relat Dis 2018; 14 (11): 1732-9.
26. Aloe L, Rocco ML, Bianchi P, et al. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med 2012; (10): 239-52.
27. Sun Q, Tang DD, Yin EG, et al. Diagnostic Significance of Serum Levels of Nerve Growth Factor and Brain Derived Neurotrophic Factor in Diabetic Peripheral Neuropathy. Med Sci Monit 2018; (24): 5943-50.
28. Mantelli F, Lambiase A, Colafrancesco V, et al. NGF and VEGF effects on retinal ganglion cell fate: new evidence from an animal model of diabetes. Eur J Ophthalmol 2014; 24 (2): 247-53.
29. Lotosh NG, Savel'eva EK, Selishcheva AA, et al. Autoantibodiesto neuron-specific proteins S100, GFAP, MBPand NGF in the serum of rats with streptozotocin- induced diabetes. Bull Exp Biol Med 2013; 155 (1): 48-51.
30. Hou Y, Linpei J, Zhang Y, et al. Activation of the NGF/TrkA signaling pathway attenuates diabetic erectile dysfunction. Oncotarget 2017; 8 (62): 105692-702.
31. Uenoyama Y, Inoue N, Nakamura S, et al. Central mechanism controlling pubertal onset in mammals: A triggering role of kisspeptin. Front. Endocrinol. (Lausanne) 2019; (10): 312.
32. Quennell JH, Howell CS, Roa J, et al. Leptin deficiency and diet-induced obesity reduce hypothalamic kisspeptin expression in mice. Endocrinology 2011; 152 (4): 1541-50.
33. Song W-J, Mondal P, Wolfe A, et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab 2014; 19 (4): 667-81.
34. Загоскин П. П., Загоскина И. П., Савельева Н.А. и др. Современные подходы к проблеме регуляции массы тела (обзор). Современные технологии в медицине 2014; 6 (3): 104-17.
35. Acar S, Paketci A, Kume Т, et al. Positive correlation of galanin with insulin resistance and triglyceride levels in obese children. Turk J Med Sci 2018; 48 (3): 560-8.
36. Duan DM, Jhang JY, WuS.etal. Modification effect of sex and obesity on the correlation of LEP polymorphisms with leptin levels in Taiwanese obese women. Mol Genet Genomic Med. URL:https://doi.org/10.1002/mgg3.1113(8 Jan 2020.
37. Baldini G, Phelan KD. The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol 2019; 241 (1): 1-33.
38. Чумакова Г.А., Отт А. В., Веселовская H. Г. и др. Патогенетические механизмы лептинорезистентности. Российский кардиологический журнал 2015; 4 (120): 107-10.
39. Lv Y, Liang Т, Wang G, et al. Ghrelin, a gastrointestinal hormone, regulates energy balance and lipid metabolism. Biosci Rep. URL: http://dx.doi.org/10.1042/BSR20181061 (25Sep2018).
40. Nesic DM, Stevanovic DM, Stankovic SD, et al. Age-dependent modulation of central ghrelin effects on food intake and lipid metabolism in rats. Eur J Pharmacol 2013; (710): 85-91.
41. Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int J Mol Sci 2017; 18(6): 1321.
42. Al-Hamodi Z, Al-Habori M, Al-Meeri A, et al. Assosiation of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and tipe 2 diabetes mellitus. Diabet Metabol Syndrome 2014; 6(1): 99.
43. Parfenova NS, Tanyansky DA. Adiponectin: effects on metabolic and cardiovascular disorders. Arterial Hypertension 2013, 19(1): 84-96.
44. Finan B' et al. Reappraisal of GIP Pharmacology for Metabolic Diseases. Trends Mol Med 2016; (22): 359-76.
45. Gupta P, Bala M, Gupta S, et al. Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs-A mechanistic revisit to understand their mode of action. Pharmacol Res 2016; (113): 636-74.
46. Волков В. П. Новые панкреатические гормоны: амилин (обзор литературы). Universum: медицина и фармакология 2014; 11 (12): 1.
47. Болотова H. В, Райгородская Н.Ю., Аверьянов А. П. и др. Особенности нейроэндокринно-иммунного статуса мальчиков-подростков с ожирением. Вопросы детской диетологии 2020; 18 (2): 15-22.
48. Yanik Т, Dominguez G, Kuhar MJ, et al. The Leu34Phe ProCART mutation leads to cocaine- and amphetamine-regulated transcript (CART) deficiency: a possible cause for obesity in humans. Endocrinology 2006; 147 (1): 39-43.
49. Rubino F, Gagner M, Gentileschi P, et al. The early effect of Roux-en-Y gastric bypass on hormones is involved in body weight regulation and glucose metabolism. AnnSurg 2004; (240): 236-42.